DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Mahalingam D, Patel M, Sachdev J. , et al.
PD-011: Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC).
Ann Oncol 2016;
27 (Suppl. 02) ii105-ii
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.